SLC5A2 and Hyperglycemia: Empagliflozin (Empa) is a novel oral anti-hyperglycemic agent that selectively inhibits sodium − glucose cotransporter-2 (SGLT2) in proximal renal tubules, thus promoting urinary glucose excretion and overcoming hyperglycemia, which is independent from insulin (Steven et al. 2017).